22 results
8-K
EX-10.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;
d. any and all claims for violation of any federal
8-K
EX-10.2
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
; false imprisonment; conversion; and disability benefits;
d. any and all claims for violation of any federal, state, or municipal statute, including
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
employment with us that is effected by us without “cause,” as defined in the Severance Plan (and other than due to death or disability), or (b)
a resignation … (a) a termination of an eligible participant’s employment with us that is effected by us without “cause” (and other than due to death or disability
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
to disability and a devastating impact on quality of life.
Izokibep has advanced to Phase 3 development in moderate-to-severe HS. In September 2023 … parameters: (a) patient global assessment of disease activity; (b) physician global assessment of disease activity; (c) patient pain scale; (d) disability
8-K
EX-99.2
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
glands and is typically accompanied by pain, malodor, drainage, and disfigurement that contribute to disability and a devastating impact on quality … of life. Patients with HS miss a greater number of days of work and have increased disability compared to the average population. In 2019, there were
8-K
EX-99.3
18ztbxen1t5z
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
7psr2hovnuwxz 7u
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
EX-10.1
ojv4s 46895lzwzl
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
8-K
EX-3.2
eog0s
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
424B4
z2g3g2fa4 87f
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
zyihoj5o28hqdq8
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-3.4
0lrc2fu9 71xxj17w
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.3
yzznzypy 71
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.9
zqh3rl5
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.4
z6oj78tbug
1 May 23
IPO registration (amended)
6:10am
S-1
EX-10.1
jd6eald0
13 Apr 23
IPO registration
5:10pm
S-1
EX-3.3
7tjzgd
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.7
q8zd7s
13 Apr 23
IPO registration
5:10pm
S-1
j0gv3iw2aw a14roy7ni
13 Apr 23
IPO registration
5:10pm